课题基金 / 基金详情

Methylation Markers for Prognosis in Endometriod Endometrial Cancers

Methylation Markers for Prognosis in Endometriod Endometrial Cancers
子宫内膜样子宫内膜癌预后的甲基化标志物
批准号:
7727348
负责人:
Tim H.-M. Huang
金额:
$10.83万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-18 至 2012-08-31
关键词:
AbbreviationsAberrant DNA MethylationAdjuvantAdjuvant TherapyAggressive behaviorBiochemicalBiologicalBiological AssayBiological MarkersBody of uterusCancer BiologyCancer PatientCessation of lifeClinicalClinical SensitivityCobraCpG Island Methylator PhenotypeCpG IslandsDNADNA MethylationDetectionDevelopmentDiagnosisDiagnostic Neoplasm StagingDiseaseDisease-Free SurvivalDistant MetastasisEarly Detection Research NetworkEndometrial CarcinomaEndometrial NeoplasmsEndometrial adenocarcinomaEndometriumEpigenetic ProcessEventExhibitsFoundationsFutureGenesGuidelinesHistologicHumanHypermethylationHysterectomyInstructionLaparotomyLeadLymph node excisionLymphocyteMalignant NeoplasmsMass Spectrum AnalysisMethodsMethylationMicrosatellite InstabilityMorbidity - disease rateNeoplasm MetastasisOperative Surgical ProceduresPathologicPatientsPhasePhase IV Clinical TrialsPreventionPrimary NeoplasmPrincipal InvestigatorProcessPrognostic MarkerRadiationRecurrenceRecurrent tumorRelapseRelative (related person)Reproduction sporesResistanceResourcesRetrospective StudiesRiskRunningSample SizeSamplingScreening procedureSensitivity and SpecificitySiteStagingStratificationStromal CellsSymptomsTestingTimeTumor stageUncertaintyUnnecessary ProceduresUterine CancerUterusValidationWomanWorkbasebisulfiteblindcancer cellcancer typecandidate validationchemotherapycohortdesignimprovedmolecular markermortalitymyometriumnovel strategiesoutcome forecastpreventprognosticprognostic indicatorprogramspromoterprospectivetumortumor progressionvalidation studies

项目摘要

项目成果

Tim H.-M. Huang的其他基金

相似基金

相关文献

中文摘要
翻译
项目2的目标是确定预测早期(阶段)复发的表观遗传生物标记物 1和ii)子宫内膜样癌(EEC)。虽然这种类型的癌症通常有很好的 预后,约10%的患者在确诊后3年内出现局部复发或远处转移。 然而,目前使用的临床病理生物学参数不足以预测哪些患者 我希望在分子标记的研究方面有所作为。 最近被证明对改善预后和更好的癌症分层很重要 子类型。我们的初步研究发现,CpG岛超甲基化是表观遗传学的一种 癌症的改变,代表了EECS的一个未开发的生物标志物来源。要确定这些 甲基化调节的基因座,我们将遵循NCI的早期检测建立的分阶段方法 研究网络。在发现步骤(第一阶段)中,将使用表观遗传微阵列方法来 54例早期原发肿瘤中27,000个人类CpG岛甲基化的综合筛查 复发的分期患者和54例未复发的患者(样本量合理)。全球分析将 确定在复发组中频繁高甲基化的候选基因座,但在非复发组中不是 一群人。在验证阶段(第二阶段),将使用基于聚合酶链式反应的检测,COBRA,以确认甲基化 在54名早期复发患者和54名未复发患者的第二个队列中的研究结果。最后一盘 然后将在2315个EEC(包括所有临床分期和肿瘤分级)中使用30个基因座进行进一步分析 在第三阶段回顾研究中。一种名为Massarray的强有力的分析方法可以有效地量化甲基化 一次检测384例临床标本中的CpG位点。这项广泛的研究将确定是否已确定 对于一些EEC患者,基因座也是不良的预后指标。临床诊断的敏感性和特异性 有希望的生物标记物将被计算并用于评估患者的复发、无病生存和 其他临床病理参数。这项研究为未来的前瞻性临床试验奠定了基础。 (第四阶段)旨在测试表观遗传生物标记物对准确预测复发EECS的效用。 相关性(请参阅说明): 拟议的工作将导致对子宫内膜癌生物学的更好理解和新的 可减少癌症的子宫癌的检测、预防和治疗方法 发病率和死亡率。
英文摘要
The objective of Project 2 is to identify epigenetic biomarkers for predicting recurrence of early stage (stages 1 and II) endometrioid endometrial carcinomas (EECs). While this type of cancer usually has a good prognosis, ~10% of patients present with local recurrence or distant metastasis within 3 years of diagnosis. The currently used clinicopathojogical parameters, however, are inadequate for predicting which patients are IiReTy to'recur andlwoijldlnosf beTiefirfrohTup^ Inlhis regardTpfofiIing of molecular markers"~ has recently been shown to be important for improved prognosis and for better stratification of cancer subtypes. Our preliminary studies have found that CpG island hypermethylation, a type of epigenetic alteration in cancer, represents an untapped resource of biomarkers for EECs. To identify these methylation-regulated loci, we will follow a phased-based approach established by the NCI's Early Detection Research Network. In the discovery step (Phase I), an epigenetic microarray approach will be used to comprehensively screen altered methylation of 27,000 human CpG islands in primary tumors of 54 early stage patients who recurred and 54 non-recurrent patients (sample size justified). Global profiling will identify candidate loci that are frequently hypermethylated in the recurrent group, but not in the non-recurrent group. In the validation phase (Phase II), a PCR-based assay, COBRA, will be used to confirm methylation findings in a second cohort of 54 early stage patients who recurred and 54 non-recurrent patients. A final set of 30 loci will then be used for further analysis in 2315 EECs (including all clinical stages and tumor grades) in the Phase III retrospective study. A robust assay, called MassARRAY, can efficiently quantify methylated CpG sites in 384 clinical samples in a single run. This extensive study will determine whether the identified loci are also poor prognostic indicators for some EEC patients. Clinical sensitivity and specificity of promising biomarkers will be calculated and used to assess patients' recurrence, disease-free survival, and other clinicopathological parameters. Such a study lays the foundation for a future prospective clinical trial (Phase IV) designed to test the utility of epigenetic biomarkers for accurate prediction of recurrent EECs. RELEVANCE (See instructions): The work proposed will lead to both an improved understanding of endometrial cancer biology and new approaches to the detection, prevention and treatment of uterine cancers which will result in reduced cancer morbidity and mortality.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PAI-1-mediated early-onset endometrial cancer
PAI-1-mediated early-onset endometrial cancer
Interrogating Epigenetic Changes in Cancer Genomes
Novel epigenetic paradigm in endometrial cancer recurrence
海外基金